- Stocks
- Healthcare
- NASDAQ: RARE

Price (delayed)

$90.35

Market cap

$6.13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.31

Enterprise value

$5.88B

The revenue has surged by 125% year-on-year and by 8% since the previous quarter

The company's gross profit has surged by 124% YoY and by 7% QoQ

The quick ratio has soared by 80% YoY but it has decreased by 12% QoQ

The equity has increased by 40% year-on-year but it has declined by 8% since the previous quarter

Ultragenyx Pharmaceutical's net income has shrunk by 73% QoQ and by 17% YoY

RARE's EPS has dropped by 72% since the previous quarter

What are the main financial stats of RARE

Market
Valuations
Earnings

Shares outstanding

67.84M

Market cap

$6.13B

Enterprise value

$5.88B

Price to earnings (P/E)

N/A

Price to book (P/B)

6.27

Price to sales (P/S)

17

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

16.37

Revenue

$359.38M

EBIT

-$350.2M

EBITDA

-$337.49M

Free cash flow

-$411.33M

Per share
Balance sheet
Liquidity

EPS

-$5.31

Free cash flow per share

-$6.08

Book value per share

$14.41

Revenue per share

$5.32

TBVPS

$19.78

Total assets

$1.51B

Total liabilities

$540.27M

Debt

$46.17M

Equity

$972.17M

Working capital

$822.43M

Debt to equity

0.05

Current ratio

7.47

Quick ratio

6.85

Net debt/EBITDA

0.73

Margins
Efficiency
Dividend

EBITDA margin

-93.9%

Gross margin

95.5%

Net margin

-97.8%

Operating margin

-93.6%

Return on assets

-22.9%

Return on equity

-36.5%

Return on invested capital

-41.4%

Return on capital employed

-25.3%

Return on sales

-97.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Ultragenyx Pharmaceutical stock price performed over time

Intraday

5.73%

1 week

12.45%

1 month

-4.1%

1 year

8.26%

YTD

-34.73%

QTD

-5.24%

How have Ultragenyx Pharmaceutical's revenue and profit performed over time

Revenue

$359.38M

Gross profit

$343.23M

Operating income

-$336.54M

Net income

-$351.43M

Gross margin

95.5%

Net margin

-97.8%

The revenue has surged by 125% year-on-year and by 8% since the previous quarter

The company's gross profit has surged by 124% YoY and by 7% QoQ

Ultragenyx Pharmaceutical's net income has shrunk by 73% QoQ and by 17% YoY

The company's operating margin has surged by 62% YoY

What is Ultragenyx Pharmaceutical's growth rate over time

What is Ultragenyx Pharmaceutical stock price valuation

P/E

N/A

P/B

6.27

P/S

17

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

16.37

RARE's EPS has dropped by 72% since the previous quarter

The equity has increased by 40% year-on-year but it has declined by 8% since the previous quarter

RARE's price to book (P/B) is 18% less than its last 4 quarters average of 7.2 but 10% more than its 5-year quarterly average of 5.4

The revenue has surged by 125% year-on-year and by 8% since the previous quarter

The P/S is 100% lower than the 5-year quarterly average of 4976.5 and 32% lower than the last 4 quarters average of 23.8

How efficient is Ultragenyx Pharmaceutical business performance

The return on assets has dropped by 67% since the previous quarter but it has increased by 13% year-on-year

RARE's return on sales has dropped by 61% since the previous quarter but it is up by 48% year-on-year

The ROE has dropped by 60% since the previous quarter but it is up by 19% year-on-year

The company's return on invested capital has shrunk by 55% QoQ but it rose by 23% YoY

What is RARE's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RARE.

How did Ultragenyx Pharmaceutical financials performed over time

The total assets is 180% more than the total liabilities

The current ratio has soared by 81% YoY but it is down by 11% QoQ

The quick ratio has soared by 80% YoY but it has decreased by 12% QoQ

Ultragenyx Pharmaceutical's debt is 95% less than its equity

The equity has increased by 40% year-on-year but it has declined by 8% since the previous quarter

Ultragenyx Pharmaceutical's debt has increased by 27% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.